Log In
BCIQ
Print this Print this
 

PIP4K2A

  Manage Alerts
Collapse Summary General Information
Company Sprint Bioscience AB
DescriptionPhosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A) inhibitor
Molecular Target Phosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat p53-negative cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$243.0M

$3.0M

$240.0M


 Deals Details
Get a free BioCentury trial today